This HTML5 document contains 91 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00380/identifier/pharmgkb/
dctermshttp://purl.org/dc/terms/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00380/identifier/pdb/
foafhttp://xmlns.com/foaf/0.1/
n28http://linked.opendata.cz/resource/mesh/concept/
n10http://linked.opendata.cz/resource/drugbank/company/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00380/identifier/pubchem-compound/
n14http://linked.opendata.cz/resource/drugbank/dosage/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00380/identifier/pubchem-substance/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00380/identifier/drugbank/
n5http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00380/identifier/national-drug-code-directory/
n13http://linked.opendata.cz/resource/drugbank/patent/
n29http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n17http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n12http://linked.opendata.cz/resource/drugbank/drug/DB00380/identifier/chemspider/
n27http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n18http://www.drugs.com/cdi/
n16http://www.rxlist.com/cgi/generic2/
n7http://linked.opendata.cz/resource/drugbank/property/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00380/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#
n25http://linked.opendata.cz/ontology/sukl/drug/
n26http://linked.opendata.cz/resource/atc/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00380/identifier/wikipedia/

Statements

Subject Item
n2:DB00380
rdf:type
n3:Drug
n3:description
An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. [PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy.
n3:dosage
n14:271B64A0-363D-11E5-9242-09173F13E4C5 n14:271B64A1-363D-11E5-9242-09173F13E4C5 n14:271B64A2-363D-11E5-9242-09173F13E4C5 n14:271B64A3-363D-11E5-9242-09173F13E4C5 n14:271B64A4-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Hasinoff BB, Herman EH: Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Cardiovasc Toxicol. 2007;7(2):140-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17652819 # Hasinoff BB: The use of dexrazoxane for the prevention of anthracycline extravasation injury. Expert Opin Investig Drugs. 2008 Feb;17(2):217-23. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18230055 # Kik K, Szmigiero L: [Dexrazoxane (ICRF-187)--a cardioprotectant and modulator of action of some anticancer drugs] Postepy Hig Med Dosw (Online). 2006;60:584-90. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17115008 # Weiss G, Loyevsky M, Gordeuk VR: Dexrazoxane (ICRF-187). Gen Pharmacol. 1999 Jan;32(1):155-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9888268 # Langer SW: Dexrazoxane for anthracycline extravasation. Expert Rev Anticancer Ther. 2007 Aug;7(8):1081-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18028016
n3:group
approved withdrawn
n3:halfLife
2.5 hours
n3:indication
For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin therapy. Also approved for the treatment of extravasation from intravenous anthracyclines.
n3:manufacturer
n10:271B649B-363D-11E5-9242-09173F13E4C5 n10:271B6499-363D-11E5-9242-09173F13E4C5 n10:271B649A-363D-11E5-9242-09173F13E4C5
owl:sameAs
n5:DB00380 n29:DB00380
dcterms:title
Dexrazoxane
adms:identifier
n9:DB00380 n11:50223 n12:64479 n19:Dexrazoxane n20:46505982 n21:PA449259 n22:71384 n23:38423-110-01 n24:CDX
n3:mechanismOfAction
The mechanism by which dexrazoxane exerts its cardioprotective activity is not fully understood. Dexrazoxane is a cyclic derivative of EDTA that readily penetrates cell membranes. Results of laboratory studies suggest that dexrazoxane (a prodrug) is converted intracellularly to a ring-opened bidentate chelating agent that chelates to free iron and interferes with iron-mediated free radical generation thought to be responsible, in part, for anthracycline-induced cardiomyopathy. It should be noted that dexrazoxane may also be protective through its inhibitory effect on topoisomerase II.
n3:packager
n10:271B6494-363D-11E5-9242-09173F13E4C5 n10:271B6497-363D-11E5-9242-09173F13E4C5 n10:271B6498-363D-11E5-9242-09173F13E4C5 n10:271B6495-363D-11E5-9242-09173F13E4C5 n10:271B6496-363D-11E5-9242-09173F13E4C5
n3:patent
n13:6727253 n13:5242901
n3:routeOfElimination
Urinary excretion plays an important role in the elimination of dexrazoxane. Forty-two percent of the 500 mg/m2 dose of dexrazoxane was excreted in the urine.
n3:synonym
(+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane (+)-(S)-4,4'-Propylenedi-2,6-piperazinedione Dexrazoxane Dextrorazoxane Dexrazoxano Dexrazoxan 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione Dexrazoxanum
n3:toxicity
Intraperitoneal, mouse LD<sub>10</sub> = 500 mg/kg. Intravenous, dog LD<sub>10</sub> = 2 gm/kg.
n3:volumeOfDistribution
* 9 to 22.6 L/m^2
n3:proteinBinding
Very low (< 2%)
n3:salt
n27:hasConcept
n28:M0018537
foaf:page
n16:dexrazoxane.htm n18:dexrazoxane.html
n3:IUPAC-Name
n7:271B64A9-363D-11E5-9242-09173F13E4C5
n3:InChI
n7:271B64AF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n7:271B64AE-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n7:271B64AB-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n7:271B64AC-363D-11E5-9242-09173F13E4C5
n3:SMILES
n7:271B64AD-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n7:271B64A7-363D-11E5-9242-09173F13E4C5 n7:271B64BF-363D-11E5-9242-09173F13E4C5
n3:logP
n7:271B64A5-363D-11E5-9242-09173F13E4C5 n7:271B64A8-363D-11E5-9242-09173F13E4C5 n7:271B64C1-363D-11E5-9242-09173F13E4C5
n3:logS
n7:271B64A6-363D-11E5-9242-09173F13E4C5
n3:pKa
n7:271B64C2-363D-11E5-9242-09173F13E4C5
n25:hasATCCode
n26:V03AF02
n3:H-Bond-Acceptor-Count
n7:271B64B5-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n7:271B64B6-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n7:271B64B0-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n7:271B64B1-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n7:271B64B3-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n7:271B64B2-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n7:271B64B4-363D-11E5-9242-09173F13E4C5
n3:absorption
IV administration results in complete bioavailability.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
24584-09-6
n3:category
n3:clearance
* 7.88 L/h/m2 [dose of 50 mg/m2 Doxorubicin and 500 mg/m2 Dexrazoxane] * 6.25 L/h/m2 [dose of 60 mg/m2 Doxorubicin and 600 mg/m2 Dexrazoxane]
n3:containedIn
n17:271B649E-363D-11E5-9242-09173F13E4C5 n17:271B649F-363D-11E5-9242-09173F13E4C5 n17:271B649C-363D-11E5-9242-09173F13E4C5 n17:271B649D-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n7:271B64BB-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n7:271B64BD-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n7:271B64BE-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n7:271B64C0-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n7:271B64BA-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n7:271B64B9-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n7:271B64BC-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n7:271B64AA-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n7:271B64B7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n7:271B64B8-363D-11E5-9242-09173F13E4C5